home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Product Recall Guidance for Drugs, Biologics, and Medical Devices: What You Need to Know

 
  October 30, 2012  
     
 
ComplianceOnline, Online Event
2012-11-29


Why Should You Attend:

Despite drug and device manufacturers’ best efforts to ensure to the quality of their products, at some point virtually all such companies will face the possibility of needing to recall one (or more) of their products. The way they evaluate these situations, what steps they decide to take, and the extent of the involvement of FDA will determine how efficiently (and with what degree of disruption to the business) the recall can be completed.

This session is designed for manufacturers of finished drugs, biologics, and medical devices, along with companies that supply important components to these manufacturers. It will provide an overview of the legal basis for product recalls and the extent of FDA’s authority over them. It will also address many practical considerations to help companies prepare for and conduct a recall, make appropriate decisions under what can otherwise be very stressful circumstances, and be prepared for the follow-up scrutiny from FDA that is almost certain to follow.

At the end of this webinar the speaker will answer questions you may have related to product recall guidance for drugs, biologics and medical devices.

Areas Covered in the Webinar:

  • Scope of FDA’s recall (and recall oversight) authority.
  • Identifying when a recall is appropriate.
  • Determining when a product recovery constitutes a “recall” and not another type of action.
  • How to prepare for a recall and steps to take to ensure that the situation is handled correctly and efficiently.
  • Considering when (or whether) to notify FDA of the recall.
  • Weighing the potential consequences of not conducting a recall.
  • Introducing a product back into the market.

Who will Benefit:

  • In-house Counsel
  • Regulatory Affairs Managers
  • Quality Assurance/Quality Control Personnel
  • Corporate Risk Managers
  • Sales/Marketing Directors
 
 
Organized by: Complianceonline
Invited Speakers: Frederick A. Stearns, is a partner in the law firm of Keller and Heckman LLP’s Washington, DC, office, where his practice involves a wide range of issues facing manufacturers of prescription and over-the-counter drugs, medical devices, dietary supplements, and cosmetics. He helps product manufacturers evaluate the need for marketing approval from FDA, pursue appropriate clearance when necessary, and address regulatory compliance issues with marketed products (including OTC drug monographs, product labeling and promotion, and current good manufacturing practices). Mr. Stearns also works with clients to respond to FDA enforcement activities, navigate the interrelationship of the patent laws and the FDA drug approval process, communicate with Agency officials, and develop innovative strategies to deal with evolving FDA regulatory requirements. In addition, Mr. Stearns works with companies to conduct FDA due diligence reviews, both for internal control/compliance assessment purposes and as part of product line or corporate acquisitions.
 
Deadline for Abstracts: 2012-11-28
 
Registration:

For Registration:

http://www.complianceonline.com/ecommerce/control/trainingFocus/~product_id=702577?channel=hummolgen 

E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.